Bridgebio Oncology Therapeutics, Inc. (BBOT)
1.815
-0.04
(-2.42%)
USD |
NASDAQ |
Nov 20, 16:00
1.815
0.00 (0.00%)
After-Hours: 16:08
Bridgebio Oncology Therapeutics Debt to Equity Ratio : 0.0081 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.0081 |
| June 30, 2026 | 0.0078 |
| March 31, 2026 | 0.0071 |
| December 31, 2025 | 0.0067 |
| September 30, 2025 | 0.0065 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | -1.102 |
| December 31, 2022 | -1.968 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Korsana Biosciences, Inc. | 0.0031 |
| IRulya Therapeutics, Inc. | 0.00 |
| PepGen Inc. | 0.1514 |
| Q32 Bio, Inc. | 0.0178 |
| Oncolytics Biotech, Inc. | -0.0546 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 346.22M |
| Total Liabilities (Quarterly) | 52.84M |
| Shareholders Equity (Quarterly) | 293.39M |
| Current Ratio | 4.083 |
| Net Debt Paydown Yield | -0.14% |